Audit Committee Position

Maureen E. O’Connell

Director

Ms. O'Connell became a Director for Sucampo in February 2013. She currently serves as the Executive Vice President, Chief Administrative Officer, and Chief Financial Officer at Scholastic Inc., a position she has held since 2007, overseeing all aspects of the company's operations. From 2005 to 2006, she was Executive Vice President and Chief Financial Officer at Affinion Group, Inc., a leading affinity direct marketer of membership, insurance, and loyalty programs. Prior, Ms. O'Connell held a series of progressively more responsible positions, including President and Chief Operating Officer and Executive Vice President, Chief Financial and Administrative Officer at Gartner, Inc., a leading technology research and advisory firm.

Ms. O'Connell has also had additional senior management positions including Executive Vice President and Chief Financial Officer at Barnes & Noble, Chief Financial Officer and Vice President at Publishers Clearing House, Senior Vice President of Finance and Marketing Analysis at BMG Direct, and Chief Financial Officer and Senior Vice President at Primedia, Inc.

She earned a bachelor's degree in accounting and economics from Stern School of Business Administration at New York University and is a Certified Public Accountant in the state of New York.

Chair

John H. Johnson

Lead Independent Director

Mr. Johnson became our Lead Independent Director in January 2016 and has been a Director of Sucampo since December 2014. He most recently served as the President and Chief Executive Officer of Dendreon Corporation, a biotechnology company focused on cancer, from 2012 to July 2014. Prior to Dendreon, Mr. Johnson served as the Chief Executive Officer of Savient Pharmaceuticals, Inc., from 2011 to 2012, and as President of Eli Lilly & Company's Oncology Unit following its 2008 acquisition of Imclone Systems, Inc. He previously held executive roles of increasing responsibility at Johnson & Johnson, where he worked from 1988 to 2007.

Mr. Johnson is currently the Chairman of the Board of Directors of Cortendo AB, a global biopharmaceutical company focused on orphan endocrine disorders. He also serves as a member of the Board of Directors of Cempra Inc., a clinical-stage pharmaceutical company, Portola Pharmaceuticals, Inc., a biopharmaceutical company, and Histogenics Corporation, a regenerative medicine company. Previously, he served as a member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Health Section Governing Board of Biotechnology Industry Organization (BIO).

Mr. Johnson earned a bachelor's degree from the East Stroudsburg University of Pennsylvania.

Member

Robert J. Spiegel M.D., FACP

Director

Dr. Spiegel became a Director for Sucampo in January 2015. He currently serves as Chief Medical Officer of PTC Therapeutics and is the President and Founder of Spiegel Consulting. Dr. Spiegel previously served as Chief Medical Officer at Schering-Plough Research Institute from 1998 to 2009, where he held positions of increasing responsibility since joining the company in 1983. At Schering-Plough, Dr. Spiegel was involved in the successful filing of over 30 New Drug Applications.

Dr. Spiegel is currently an Associate Professor at Weill Cornell Medical Center. He serves on the Board of Directors and on the advisory committees of a number of companies, including clinical-stage biotechnology companies Edge Therapeutics and Geron Corporation, as well as Avior Computing Corporation, a risk and compliance management software company, and Warburg Pincus, a global private equity investment institution.

Dr. Spiegel earned a bachelor's degree, cum laude, from Yale University and a medical degree from the University of Pennsylvania.

Member

Timothy P. Walbert

Director

Mr. Walbert became a Director of Sucampo in October 2015. He currently serves as President and Chief Executive Officer and Chairman of the Board of Directors of Horizon Pharma plc. Prior to Horizon Pharma, he served as President, Chief Executive Officer and Director of IDM Pharma, Inc. from May 2007 until the acquisition of IDM by Takeda in June 2009, and as Executive Vice President, Commercial Operations of NeoPharm, Inc. from 2006 to 2007. From 2001 to 2005, Mr. Walbert was the Divisional Vice President and General Manager, Immunology, and Divisional Vice President, Global Cardiovascular Strategy at Abbott, now AbbVie, where he led the global development and launch of the multi-indication biologic HUMIRA. Earlier in his career, he held the position of Director, Celebrex North America and Arthritis Team Leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company, now Pfizer, as well as sales and marketing roles with increasingly responsibility at G.D. Searle, Merck & Co., Inc. and Wyeth Pharmaceuticals, Inc., now Pfizer.

Mr. Walbert is currently chairman of Egalet Corporation and the Illinois Biotechnology Industry Organization (iBIO). Mr. Walbert is a member of the Board of Directors of XOMA Corporation, the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Innovation Organization (BIO), World Business Chicago (WBC), the Greater Chicago Arthritis Foundation and the Illinois Innovation Council.

Mr. Walbert earned a bachelor's degree from Muhlenberg College.

Member

Audit Committee Charter

Download
Compensation Committee Position

Timothy P. Walbert

Director

Mr. Walbert became a Director of Sucampo in October 2015. He currently serves as President and Chief Executive Officer and Chairman of the Board of Directors of Horizon Pharma plc. Prior to Horizon Pharma, he served as President, Chief Executive Officer and Director of IDM Pharma, Inc. from May 2007 until the acquisition of IDM by Takeda in June 2009, and as Executive Vice President, Commercial Operations of NeoPharm, Inc. from 2006 to 2007. From 2001 to 2005, Mr. Walbert was the Divisional Vice President and General Manager, Immunology, and Divisional Vice President, Global Cardiovascular Strategy at Abbott, now AbbVie, where he led the global development and launch of the multi-indication biologic HUMIRA. Earlier in his career, he held the position of Director, Celebrex North America and Arthritis Team Leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company, now Pfizer, as well as sales and marketing roles with increasingly responsibility at G.D. Searle, Merck & Co., Inc. and Wyeth Pharmaceuticals, Inc., now Pfizer.

Mr. Walbert is currently chairman of Egalet Corporation and the Illinois Biotechnology Industry Organization (iBIO). Mr. Walbert is a member of the Board of Directors of XOMA Corporation, the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Innovation Organization (BIO), World Business Chicago (WBC), the Greater Chicago Arthritis Foundation and the Illinois Innovation Council.

Mr. Walbert earned a bachelor's degree from Muhlenberg College.

Chair

Robert J. Spiegel M.D., FACP

Director

Dr. Spiegel became a Director for Sucampo in January 2015. He currently serves as Chief Medical Officer of PTC Therapeutics and is the President and Founder of Spiegel Consulting. Dr. Spiegel previously served as Chief Medical Officer at Schering-Plough Research Institute from 1998 to 2009, where he held positions of increasing responsibility since joining the company in 1983. At Schering-Plough, Dr. Spiegel was involved in the successful filing of over 30 New Drug Applications.

Dr. Spiegel is currently an Associate Professor at Weill Cornell Medical Center. He serves on the Board of Directors and on the advisory committees of a number of companies, including clinical-stage biotechnology companies Edge Therapeutics and Geron Corporation, as well as Avior Computing Corporation, a risk and compliance management software company, and Warburg Pincus, a global private equity investment institution.

Dr. Spiegel earned a bachelor's degree, cum laude, from Yale University and a medical degree from the University of Pennsylvania.

Member

Paul Edick

Director

Mr. Paul Edick became a Director for Sucampo in July 2016. He currently serves as Founding Partner at 3G Advisors, a consultancy to the pharmaceutical, healthcare and healthcare investor communities. From 2010 to 2014, Mr. Edick was Chief Executive Officer and board member of Durata Therapeutics, a public biopharmaceutical company addressing the growing need for new antibiotics to treat infectious diseases. Prior to Durata, he was Chief Executive Officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus investment search vehicle, and prior to that, he was Chief Executive Officer at MedPoint Healthcare, Inc. Mr. Edick has also held a number of senior positions at GD Searle & Company, and at Pharmacia Corporation following its acquisition of the company, culminating in his appointment as Pharmacia's Group Vice President and President for Asia and Latin America.

He is a member of the Board of Directors of PDL BioPharma, Inc., NewLink Genetics, Inc. and Neos Therapeutics, Inc. Mr. Edick is also Chairman of the Board of Iterum Therapeutics, a private company.

Mr. Edick earned a bachelor's degree in Psychology from Hamilton College in Clinton, NY.

Member

Karen Smith, M.D., Ph.D., M.B.A., LLM.

Director

Karen Smith became a Director for Sucampo in July 2017. She currently serves as Executive Vice President, R&D and Chief Medical Officer of Jazz Pharmaceuticals, a position she has held since May 2017. Prior to that, Dr. Smith served as Senior Vice President, Global Head of R&D and Chief Medical Officer of Jazz Pharmaceuticals from April 2015 until May 2017. From January 2011 to March 2015, she was Senior Vice President, Global Medical Affairs and Global Therapeutic Area Head (Dermatology) for Allergan, Inc., a multi-specialty health care company. From October 2007 to December 2010, Dr. Smith served initially as Vice President, External Medical Relations and then Vice President, Global Development at AstraZeneca LP, a global innovation-driven biopharmaceutical company. From 2002 to 2007, Dr. Smith held a variety of management and medical roles with Bristol-Myers Squibb Company, a global biopharmaceutical company, in Australia, Canada, and the United States, most recently as the Head of U.S. Clinical Operations. In 2001, Dr. Smith was the Chief Executive Officer of Boron Molecular, a specialist fine chemicals manufacturing company. She currently serves on the Women's Advisory Board for Ironman Corporation. Dr. Smith holds a B.A.Sc. and a B.Sc. from the Curtin University of Technology, an M.D. from the University of Warwick, a Ph.D. in oncology molecular genetics from the University of Western Australia, an M.B.A. from the University of New England (Australia) and a L.L.M. in medical law from the University of Salford.

Member

Compensation Committee Charter

Download
Nominating and Corporate Governance Committee Position

John H. Johnson

Lead Independent Director

Mr. Johnson became our Lead Independent Director in January 2016 and has been a Director of Sucampo since December 2014. He most recently served as the President and Chief Executive Officer of Dendreon Corporation, a biotechnology company focused on cancer, from 2012 to July 2014. Prior to Dendreon, Mr. Johnson served as the Chief Executive Officer of Savient Pharmaceuticals, Inc., from 2011 to 2012, and as President of Eli Lilly & Company's Oncology Unit following its 2008 acquisition of Imclone Systems, Inc. He previously held executive roles of increasing responsibility at Johnson & Johnson, where he worked from 1988 to 2007.

Mr. Johnson is currently the Chairman of the Board of Directors of Cortendo AB, a global biopharmaceutical company focused on orphan endocrine disorders. He also serves as a member of the Board of Directors of Cempra Inc., a clinical-stage pharmaceutical company, Portola Pharmaceuticals, Inc., a biopharmaceutical company, and Histogenics Corporation, a regenerative medicine company. Previously, he served as a member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Health Section Governing Board of Biotechnology Industry Organization (BIO).

Mr. Johnson earned a bachelor's degree from the East Stroudsburg University of Pennsylvania.

Member

Maureen E. O’Connell

Director

Ms. O'Connell became a Director for Sucampo in February 2013. She currently serves as the Executive Vice President, Chief Administrative Officer, and Chief Financial Officer at Scholastic Inc., a position she has held since 2007, overseeing all aspects of the company's operations. From 2005 to 2006, she was Executive Vice President and Chief Financial Officer at Affinion Group, Inc., a leading affinity direct marketer of membership, insurance, and loyalty programs. Prior, Ms. O'Connell held a series of progressively more responsible positions, including President and Chief Operating Officer and Executive Vice President, Chief Financial and Administrative Officer at Gartner, Inc., a leading technology research and advisory firm.

Ms. O'Connell has also had additional senior management positions including Executive Vice President and Chief Financial Officer at Barnes & Noble, Chief Financial Officer and Vice President at Publishers Clearing House, Senior Vice President of Finance and Marketing Analysis at BMG Direct, and Chief Financial Officer and Senior Vice President at Primedia, Inc.

She earned a bachelor's degree in accounting and economics from Stern School of Business Administration at New York University and is a Certified Public Accountant in the state of New York.

Member

Paul Edick

Director

Mr. Paul Edick became a Director for Sucampo in July 2016. He currently serves as Founding Partner at 3G Advisors, a consultancy to the pharmaceutical, healthcare and healthcare investor communities. From 2010 to 2014, Mr. Edick was Chief Executive Officer and board member of Durata Therapeutics, a public biopharmaceutical company addressing the growing need for new antibiotics to treat infectious diseases. Prior to Durata, he was Chief Executive Officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus investment search vehicle, and prior to that, he was Chief Executive Officer at MedPoint Healthcare, Inc. Mr. Edick has also held a number of senior positions at GD Searle & Company, and at Pharmacia Corporation following its acquisition of the company, culminating in his appointment as Pharmacia's Group Vice President and President for Asia and Latin America.

He is a member of the Board of Directors of PDL BioPharma, Inc., NewLink Genetics, Inc. and Neos Therapeutics, Inc. Mr. Edick is also Chairman of the Board of Iterum Therapeutics, a private company.

Mr. Edick earned a bachelor's degree in Psychology from Hamilton College in Clinton, NY.

Member

Karen Smith, M.D., Ph.D., M.B.A., LLM.

Director

Karen Smith became a Director for Sucampo in July 2017. She currently serves as Executive Vice President, R&D and Chief Medical Officer of Jazz Pharmaceuticals, a position she has held since May 2017. Prior to that, Dr. Smith served as Senior Vice President, Global Head of R&D and Chief Medical Officer of Jazz Pharmaceuticals from April 2015 until May 2017. From January 2011 to March 2015, she was Senior Vice President, Global Medical Affairs and Global Therapeutic Area Head (Dermatology) for Allergan, Inc., a multi-specialty health care company. From October 2007 to December 2010, Dr. Smith served initially as Vice President, External Medical Relations and then Vice President, Global Development at AstraZeneca LP, a global innovation-driven biopharmaceutical company. From 2002 to 2007, Dr. Smith held a variety of management and medical roles with Bristol-Myers Squibb Company, a global biopharmaceutical company, in Australia, Canada, and the United States, most recently as the Head of U.S. Clinical Operations. In 2001, Dr. Smith was the Chief Executive Officer of Boron Molecular, a specialist fine chemicals manufacturing company. She currently serves on the Women's Advisory Board for Ironman Corporation. Dr. Smith holds a B.A.Sc. and a B.Sc. from the Curtin University of Technology, an M.D. from the University of Warwick, a Ph.D. in oncology molecular genetics from the University of Western Australia, an M.B.A. from the University of New England (Australia) and a L.L.M. in medical law from the University of Salford.

Member

Nominating and Corporate Governance Committee Charter

Download